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MicroRNAs (miRNAs) function cell-intrinsically to regulate gene ex-
pression by base-pairing to complementary mRNA targets while in
association with Argonaute, the effector protein of the miRNA-
mediated silencing complex (miRISC). A relatively dilute popula-
tion of miRNAs can be found extracellularly in body fluids such
as human blood plasma and cerebrospinal fluid (CSF). The remark-
able stability of circulating miRNAs in such harsh extracellular envi-
ronments can be attributed to their association with protective
macromolecular complexes, including extracellular vesicles (EVs),
proteins such as Argonaut 2 (AGO2), or high-density lipoproteins.
The precise origins and the potential biological significance of var-
ious forms of miRNA-containing extracellular complexes are poorly
understood. It is also not known whether extracellular miRNAs in
their native state may retain the capacity for miRISC-mediated tar-
get RNA binding. To explore the potential functionality of circulat-
ing extracellular miRNAs, we comprehensively investigated the
association between circulating miRNAs and the miRISC Argonaute
AGO2. Using AGO2 immunoprecipitation (IP) followed by small-RNA
sequencing, we find that miRNAs in circulation are primarily associ-
ated with antibody-accessible miRISC/AGO2 complexes. Moreover,
we show that circulating miRNAs can base-pair with a target mimic
in a seed-based manner, and that the target-bound AGO2 can be
recovered from blood plasma in an ∼1:1 ratio with the respective
miRNA. Our findings suggest that miRNAs in circulation are largely
contained in functional miRISC/AGO2 complexes under normal
physiological conditions. However, we find that, in human CSF,
the assortment of certain extracellular miRNAs into free miRISC/
AGO2 complexes can be affected by pathological conditions such
as amyotrophic lateral sclerosis.
Argonaut | extracellular microRNA | human plasma | cerebrospinal fluid |
AGO2
MicroRNAs (miRNAs) are endogenous small RNAs of 21 to22 nucleotides that regulate gene expression by base-
pairing to mRNA targets and causing their translation repres-
sion and/or degradation (1–3). Depending on the cell type, there
can be ∼10,000 to 120,000 miRNA molecules per cell (4). Al-
though miRNAs function cell-intrinsically, extracellular miRNAs
can be found in tissue culture medium (5) or circulating in body
fluids, such as human blood plasma (6, 7) and cerebrospinal fluid
(CSF) (8). Many of the miRNAs detected in circulation are
known to be expressed tissue-specifically, and profiles of circu-
lating miRNAs can change depending on physiological or path-
ological conditions (9, 10). Therefore, circulating miRNAs can
reflect the status of internal tissues and organs, and hence can
serve as diagnostic biomarkers for diseases, including cancer (11,
12), neurological disease (10, 13), and liver toxicity (14).
The remarkable stability of miRNAs in cell-free body fluids
can be attributed to their reported association with various
macromolecular complexes, including membranous extracellular
vehicles (EVs) (15), high-density lipoproteins (16), or the
miRNA-mediated silencing complex (miRISC) effector protein
Argonaute 2 (AGO2) (5–7). Reports vary on the distribution of
circulating miRNAs among such distinct carrier complexes.
Numerous reports show that miRNAs can be readily extracted
from fractions of blood plasma or extracellular culture medium
enriched for EVs (11, 17–19). In contrast, extracellular miRNAs
have been found associated with apparent ribonucleoprotein
(RNP) complexes that are appreciably smaller than EVs. Size-
exclusion chromatography of human plasma demonstrated that
miRNA-associated AGO2 complexes were enriched in fractions
corresponding to the approximate size of Argonaute, and not in
the fractions corresponding to 100-nm-diameter vesicles (6). In a
qRT-PCR profiling of 375 miRNAs in these size-exclusion
chromatography fractions of human plasma, greater than 67%
of the assayed miRNAs were associated with fractions containing
AGO2 protein, and a corresponding portion of plasma miRNAs
could be recovered by AGO2 immunoprecipitation from plasma
(6). Similarly, other studies have indicated that a significant
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portion of miRNAs in blood plasma and/or cell culture media
could be separated from EVs by ultracentrifugation (7) and
fractionated together with AGO2 in subsequent ultrafiltration
(5, 20). It is possible that the yield of miRNAs recovered from
EVs could depend on whether the particular protocol used to
enrich for EVs can effectively distinguish between miRNAs en-
capsulated within EVs or, alternatively, miRNAs associated with
the exterior surface of the EVs (Fig. 1).
The underlying mechanisms by which cells export miRNAs are
poorly understood, and it is not known which extracellular carrier
complexes, such as EVs or free AGO2, may reflect active versus
passive export of miRNAs from cells. In some disease contexts
(14, 21, 22), cells can release miRNAs passively due to injury,
chronic inflammation, apoptosis, or necrosis. There is also evi-
dence that cells can actively export miRNAs by selectively pack-
aging them into particular carriers (23–27), perhaps to maintain
cell homeostasis or send signals to recipient cells. For example,
certain cancer cell lines appear to selectively export let-7 family
miRNAs into the extracellular milieu via EVs, conceivably to
maintain their oncogenic state (28). Similarly, miR-126 released
into apoptotic bodies by cells during atherosclerosis is reported to
communicate paracrine alarm signals to vascular cells, which in
turn produce protective chemokines (24).
The apparent stability of miRNAs in circulation supports the
hypothesis that extracellular miRNAs could reflect a mode of
RNA-mediated intercellular communication, such that miRNAs
produced in one cell could function to regulate gene expression
in another cell. In this regard, there is evidence that miRNAs in
circulation could be functional in recipient cells, either in cell
culture or in the intact mouse (15, 29–32). However, the con-
centration of extracellular miRNAs in blood plasma is in the
order of ∼5 pM (33), far less than the concentrations considered
to be minimal for intracellular function, which are estimated to
be at least ∼26 pM (34), or even in the nanomolar range when
considering intratarget pool competition in the cytoplasm (4).
Therefore, the sparse concentration of miRNAs in circulation
would need to be dramatically concentrated upon uptake in
order to function in a recipient cell. However, it is possible that
the miRNAs detected in circulation may correspond to a diluted
sample of more concentrated (and thus potentially functional)
populations of extracellular miRNAs in the interstitial milieu
of tissues.
In this study, we comprehensively characterized the profiles of
circulating miRNAs associated with AGO2 in human plasma and
CSF by immunoprecipitating AGO2 under native conditions, fol-
lowed by small RNA sequencing. Our studies show that a major
fraction of miRNAs in circulation are primarily associated with
AGO2 complexes that readily bind to anti-AGO2 antibodies under
native conditions, and therefore are not enclosed within vesicles. We
also find that a subfraction of the population of certain circulating
miRNAs are inaccessible for AGO2 immunoprecipitation and
therefore apparently are associated with other complexes, such as
other Argonaute proteins or the interiors of extracellular vesicles.
We find that, for particular miRNAs in CSF samples, the AGO2
association profiles can differ significantly under pathological con-
ditions such as elevated intracranial pressure (ICP) or amyotrophic
lateral sclerosis (ALS) compared with healthy CSF samples, sug-
gesting that AGO2 immunoprecipitation can potentially enhance
the resolution of miRNA biomarker screening.
We assessed the target binding potential of miRISC in circu-
lation by introducing an affinity matrix-linked target mimic into
human plasma samples under native conditions and subsequently
assessing depletion and recovery of the complementary miRNA
via quantitative real-time PCR (qRT-PCR) and small-RNA se-
quencing. By using complementary target RNA against two
distinct miRNAs, we show that the miRNAs associated with free
miRISC/AGO2 in circulation can base-pair with their RNA
targets in a seed-guided manner, and therefore could potentially
function in the event that they were to be taken up by cells in
sufficient quantities.
Results
miRNAs Can Be Depleted and Recovered from Human Blood Plasma
by Native Immunoprecipitation with Anti-AGO2 Antibody. In order
to identify plasma miRNAs associated with free, antibody-accessible
AGO2, we immunoprecipitated AGO2 from 200 μL of human
blood plasma samples using 10 μg of anti-AGO2 antibody with
overnight incubation (Fig. 2A, SI Appendix, Fig. S1, and Materials
and Methods). Anti-AGO2 Western blot analysis showed a band at
∼97 kDa, which is the expected molecular weight of AGO2, in the
AGO2 immunoprecipitation, while there was no such band evident
for control IgG immunoprecipitation (Fig. 2B).
To confirm that the 97-kDa band reacting with anti-AGO2 in
our Western blots was indeed immunoprecipitated AGO2 and not
cross-reacting protein(s), we conducted mass spectrometry analy-
sis of gel sections cut at specific ranges of molecular weights
(Fig. 2C). Mass spectrometry analysis confirmed the presence of
AGO2 protein in AGO2 immunoprecipitation at the correct
molecular weight section (slice C, 75 to 100 kDa) and the absence
of AGO2 in the control IgG immunoprecipitation. AGO2 protein
was only detected in the gel slice corresponding to ∼75 to 100 kDa
and not at any other molecular weight (Fig. 2D and Dataset S1).
qRT-PCR analysis showed that miR-16 was depleted from
plasma by AGO2 immunoprecipitation compared with control
IgG immunoprecipitation and that the depleted miR-16 could be
recovered from the immunoprecipitated beads (Fig. 2E). This
indicates that miR-16 in human blood plasma is largely associ-
ated with antibody-accessible AGO2. To comprehensively iden-
tify the miRNAs associated with these complexes, we conducted
small-RNA sequencing of RNA remaining in the supernatant
after AGO2 immunoprecipitation and RNA recovered from the
AGO2-immunoprecipitated beads. Quantitative analysis of
RNA-seq data was conducted by normalizing the UMI counts of
the circulating miRNA across the samples to a standard quantity
of spike-in miRNA (cel-miR-39) that was added to each sample
Fig. 1. Model of circulating miRNA association with carrier complexes. A
portion of circulating miRNAs are proposed to be associated with free
miRISC/AGO2 complexes that are accessible for base pairing to target mimic
oligonucleotides (blue enclosure), a subset of which are accessible for
binding to anti-AGO2 antibodies (pink enclosure).










































at the Trizol extraction step, thus allowing a direct measurement
of depletion and recovery (Materials and Methods). We observed
that essentially all of the miRNAs detected by RNA sequencing were
at least partially depleted from plasma by AGO2 immunoprecipitation
compared with control IgG immunoprecipitation (Fig. 3A), sug-
gesting that many plasma miRNAs are associated with antibody-
accessible AGO2. Many of the depleted miRNAs seem to be effi-
ciently recovered from the anti-AGO2 beads, with some exceptions,
Fig. 2. Immunoprecipitation of circulating miRNA from human blood plasma. (A) Schematic showing the immunoprecipitation (IP) protocol where bead-
conjugated mouse AGO2 antibodies are incubated overnight at 4 °C in blood plasma under native conditions (absence of detergent or any other additive).
The beads are removed by magnetizing, and RNA extracted from the supernatant is subjected to qRT-PCR and/or small-RNA sequencing to detect the miRNAs
depleted by AGO2 immunoprecipitation. The magnetized beads are processed either for RNA extraction followed by qRT-PCR and/or small-RNA sequencing
to assess miRNA recovery, or for protein extraction and subsequent Western blotting using a rabbit anti-AGO2 antibody (orthogonal to the immunopre-
cipitation antibody). (B) Western blot probed with anti-AGO2 antibody to assess AGO2 associated with the captured beads following AGO2 immunopre-
cipitation. The red arrow shows that an AGO2 band at ∼97 kDa is detected in the anti-AGO2 immunoprecipitate but absent from the control IgG
immunoprecipitate. (C) Coomassie staining following SDS/PAGE shows the sections that were sliced according to ranges of molecular weight and subjected to
mass spectrometry (Dataset S1). (D) Summary of AGO2 peptide spectral counts as determined by tandem mass spectrometry. AGO2 was only detected in slice
C (75 to 100 kDa) in immunoprecipitation using anti-AGO2. (E) qRT-PCR analysis of miR-16 levels in the plasma supernatant and beads to display depletion
and recovery following immunoprecipitation of control IgG and AGO2. Relative miRNA levels are normalized to the mean miRNA levels of control IgG su-
pernatant samples following normalization of all samples to the cel-miR-39 spike-in. Error bars represent SE of mean (SEM) derived from three or more
experiments. Statistical significances were determined by Student t tests (P ≤ 0.05).


























































especially among the less abundant miRNAs (Fig. 3B). Across all
miRNAs detectable in human blood plasma samples (n = 2) by our
small RNA sequencing, we observed an average depletion of 78%
(Fig. 3C). We identified 304 miRNAs that were depleted at least
50% by anti-AGO2 immunoprecipitation and 19 miRNAs that
were less than 50% depleted by AGO2 immunoprecipitation
(Fig. 3C). Of the 130 miRNAs that we detected by small RNA
sequencing in 5 biological replicates, 114 were depleted more than
50% in a statistically significant manner (P ≤ 0.05), while 11
miRNAs were depleted less than 50% in a statistically significant
manner, and the remaining 5 miRNAs showed an average de-
pletion of less than 50% but did not meet statistical significance
(SI Appendix, Fig. S2, and Dataset S2).
These depletion and recovery data suggest that most circulating
miRNAs in our human plasma samples are predominantly associ-
ated with AGO2 complexes that are free to interact with anti-
AGO2 antibodies under the conditions of our immunoprecipita-
tion experiments. The poorly immunoprecipitated miRNAs could
be associated with AGO2 complexes that have their anti-AGO2
binding epitopes masked by other proteins, or they could be asso-
ciated with other RNA-binding proteins, such as AGO1/3/4, or they
could be enclosed within vesicles (Fig. 1). It should be noted that
our immunoprecipitation experiments are conducted using essen-
tially native plasma, and, in particular, the immunoprecipitation
conditions do not include any detergent and hence should maintain
any extracellular membranous vesicles in their intact state.
Most of the miRNAs in Normal Human CSF Can Be Depleted by AGO2
Immunoprecipitation. We conducted AGO2 immunoprecipitation
using 250 μL of human CSF samples from a cohort of healthy
individuals (n = 3) and assessed miRNA depletion using small
RNA sequencing (Fig. 4A). For the 203 miRNAs represented in
our sequencing data, the average depletion was 62% (Fig. 4D).
Out of the 155 miRNAs that were at least 50% depleted from CSF
by anti-AGO2 antibodies, 126 miRNAs showed statistical signifi-
cance, and, out of the 48 miRNAs that exhibited less than 50%
depletion, 22 miRNAs showed statistical significance (Dataset S3).
This suggested that the majority of the miRNAs in CSF samples
from healthy individuals are associated with antibody-accessible
AGO2 complexes.
The results reported above, showing immunoprecipitation of
miRNAs from plasma and CSF using anti-AGO2 antibodies,
suggest that a major portion of circulating miRNAs in blood
plasma and CSF are associated with AGO2 that is accessible to
bind anti-AGO2 antibody. However, mere recovery of miRNA
from anti-AGO2 IP does not in itself confirm that the miRNAs
are loaded into Argonaute in the standard manner, or even di-
rectly associated with Argonaute. If the miRNAs are loaded into
AGO2, then there are two predictions: (i) circulating miRNAs
should exhibit the capacity to bind to a target via seed-mediated
base pairing and (ii) miRNAs and their AGO2 partner proteins
should be present in an ∼1:1 ratio in plasma or CSF. In the
following two sections, we test these predictions.
Fig. 3. Plasma miRNAs can be depleted by AGO2 immunoprecipitation. (A) Small-RNA sequencing of RNAs extracted from plasma supernatant following
control IgG (x-axis; n = 2) and AGO2 (y-axis; n = 2) immunoprecipitation. A cel-miR-39 spike-in was included to normalize the data to the original sample
volume, allowing a direct comparison of the yields of miRNAs from control and experimental samples. Essentially all of the miRNAs detected in the se-
quencing dataset are below the diagonal line, indicating a general depletion of miRNAs from plasma by AGO2 immunoprecipitation. (B) Small RNA se-
quencing analysis of depletion vs. recovery in plasma. Depletion was calculated by subtracting AGO2 immunoprecipitated supernatant miRNA counts from
control IgG immunoprecipitated supernatant miRNA counts, and recovery was calculated by subtracting control IgG-immunoprecipitated miRNA counts from
the AGO2-immunoprecipitated miRNA counts. (C) Distribution of the percent depletions by anti-AGO2 immunoprecipitation for 323 miRNAs (n = 2 samples).
Average depletion was ∼78% (gray dashed line); 19 of the 323 miRNAs were depleted less than 50% (blue dashed line). The positions of miR-16 and let-7a
are labeled.










































Circulating miRNAs Can Base-Pair Sequence-Specifically to a Target Mimic
Oligonucleotide. In order to assess whether AGO2-associated plasma
miRNAs are accessible for base-pairing with a target, we incu-
bated 5 pmol of biotinylated 2′-O-methyl RNA oligonucleotides
(conjugated to streptavidin beads) that were fully complemen-
tary to either miR-16 or let-7a in plasma for 15 min at room
temperature (Fig. 5 A and B, SI Appendix, Fig. S3, and Materials
and Methods).
qRT-PCR data showed that a target oligonucleotide comple-
mentary to miR-16 depleted ∼90% of miR-16 from plasma,
whereas let-7a was not depleted by the miR-16 target oligo
(Fig. 5C). Conversely, using a target oligo complementary to let-
7a, we observed depletion (∼50% via qRT-PCR) of let-7a from
plasma and essentially no depletion of miR-16 (Fig. 5C). These
results indicate that the miR-16 and let-7a complementary targets
specifically depleted their cognate miRNAs from human blood
plasma. Consistent with sequence-specific capture, miR-16 (but
not let-7a) was recovered from miR-16 target oligonucleotide-
conjugated beads (Fig. 5D and SI Appendix, Fig. S4; recovery
protocol described in Materials and Methods).
If the miR-16 target oligonucleotides were capturing miR-16
miRISC through Argonaute-facilitated (seed sequence-medi-
ated) base pairing, then we expect that the miR-16 target should
also deplete other members of the miR-16 seed family from
plasma. We conducted qRT-PCR assays on RNA from plasma
incubated with miR-16 target oligonucleotide or scrambled oligo
to measure the specific depletion of a selected set of miRNAs,
including the miR-16 family members miR-16, miR-15a, and
miR-195 and other non–miR-16 family miRNAs, miR-451, miR-
92, miR-223, miR-1249, miR-22, miR-126, miR-142-3p, miR-
4454, and miR-191. We observed that the target oligonucleo-
tides complementary to miR-16 depleted the miR-16 family, but
did not appreciably deplete the non–miR-16 family miRNAs
tested, with the exception of miR-191 (SI Appendix, Fig. S5; see
additional discussion below regarding this partial depletion of
miR-191 by miR-16 target oligo).
In order to comprehensively evaluate the sequence specificity
of binding of circulating miRNAs with a defined target sequence,
we conducted small RNA sequencing from the plasma super-
natant (to assess depletion) and the bead-bound miRNAs (to
assess recovery) after incubation of the beads containing the
miR-16 target oligo. Small RNA sequencing analysis showed
statistically significant depletion of miR-16 and the miR-16 seed
family members miR-15a, miR-15b, and miR-195. Interestingly,
we also observed depletion of members of another seed family of
miRNAs, miR-103 and miR-107 (Fig. 6 A and B). Depletion of
the miR-103/107 family can be accounted for by the fact that the
miR-103/107 seed (GCAGCAU) is similar enough to the miR-16
seed (AGCAGCA) such that miR-16 target oligonucleotide
contains a nucleotide 2–7 hexamer seed match to miR-103/107
Fig. 4. The profiles of miRNAs depleted by AGO2 immunoprecipitation from healthy CSF samples and CSF from patients with ALS or ICP. (A) Small-RNA
sequencing of supernatant following control IgG (x-axis; n = 3) and AGO2 (y-axis; n = 3) immunoprecipitation in CSF from healthy individuals. Almost all
miRNAs are below the diagonal line, indicating a general depletion of almost all miRNAs in CSF from healthy individuals. (B) Small-RNA sequencing of su-
pernatant following control IgG (x-axis; n = 3) and AGO2 (y-axis; n = 3) immunoprecipitation in CSF from ALS patients. Fewer miRNAs (than in A) are below
the diagonal line for the ALS samples, indicating an increase in miRNAs refractory to immunoprecipitation in the CSF from ALS patients compared with
healthy individuals. (C) Small-RNA sequencing of supernatant following control IgG (x-axis; n = 2) and AGO2 (y-axis; n = 2) immunoprecipitation in CSF from
patients with ICP. Again, fewer miRNAs (than in A) are below the diagonal line for the ICP samples, indicating an increase in miRNAs refractory to immu-
noprecipitation in the CSF from ICP patients compared with healthy individuals. For A–C, the red dots represent the miRNAs that are refractory to depletion
(P ≤ 0.05) in ALS CSF (B) but are efficiently depleted from control CSF (P ≤ 0.05 or P ≤ 0.1; A); the turquoise dots represent the miRNAs that are efficiently
depleted (P ≤ 0.05) in healthy control CSF (A) but refractory to depletion (P ≤ 0.05) by AGO2 immunoprecipitation in CSF from ICP patients (C). miR-203b-5p is
refractory to depletion in both ALS and ICP CSF samples compared with CSF samples from healthy individuals, and thus represented in an underlined (tur-
quoise) red dot in A. (D–F) Distribution of miRNA depletion by AGO2 immunoprecipitation in healthy control CSF (D), ALS CSF (E), and ICP CSF (F). The average
depletions (dashed gray lines) are ∼62%, ∼45%, and 48%, respectively. The UMI count for each sample is normalized to the spike-in cel-miR-39.


























































(SI Appendix, Fig. S6). Similar to the qRT-PCR data reported
above, our small RNA sequencing data also indicated a partial
depletion (albeit not statistically significant by Deseq2 analysis)
of miR-191 with the target oligo complementary to miR-16 (SI
Appendix, Fig. S6J). We note that miR-191 has partial comple-
mentarity in its seed region and 3′ supplementary region to the
miR-16 target/capture oligo, which perhaps could account for
the partial depletion of miR-191 by this miR-16 target oligonu-
cleotide. Only the recovery (from beads) of miR-16 was statis-
tically significant (Deseq2 analysis) compared to the incubation
of a scrambled oligo (SI Appendix, Fig. S6 A and B) that did not
have a specific target. We were unable to recover all of the miR-
16 that was depleted, perhaps due to degradation during the
lengthy recovery protocol that includes a high-temperature in-
cubation (SI Appendix, Fig. S6).
Similarly, small RNA sequencing showed that let-7a and its
family members, let-7b, let-7c, and let-7d, were depleted from
plasma when a target fully complementary to let-7a was used
(Fig. 6 C and D). let-7b, let-7c, and let-7d differ in sequence from
let-7a in their nonseed sequences, indicating that the target oli-
gonucleotide captures these miRNAs by seed-mediated base-
pairing, characteristic to miRISC target recognition (SI Appen-
dix, Fig. S7). qPCR assays indicated that let-7a was ∼50% de-
pleted from plasma by the let-7a complementary target mimic
oligonucleotide (Fig. 5C). However, small-RNA sequencing data
showed that let-7a was ∼80% depleted by the same let-7a target
mimic (SI Appendix, Fig. S7A). This apparent discrepancy be-
tween qPCR and small RNA sequencing could reflect a relaxed
specificity of the qRT-PCR assay for let-7a, such that other
(relatively less depleted) let-7 family members may have been
Fig. 5. Target mimic oligonucleotides can base-pair with plasma miRNAs, capturing the cognate miRNA, along with AGO2. (A) Sequence complementarity of
miR-16 and let-7a target mimic oligonucleotides to their cognate miRNAs. There are five extra nucleotide overhangs on the 5′ and 3′ ends of each of the
target mimic oligonucleotides. (B) Schematic showing the affinity matrix-linked target mimic assay where the biotinylated target mimic is conjugated to
streptavidin beads and incubated with native plasma, without detergent or additives, for 15 min at room temperature. The beads were removed by mag-
netizing, and the supernatant and the magnetized beads were processed for RNA extraction or protein gel electrophoresis and Western blotting using anti-
AGO2 antibody. (C) qRT-PCR analysis of the plasma supernatant following the incubation with a target mimic oligo against miR-16 or let-7a. miR-16 was
depleted from plasma with a target oligo against miR-16, whereas let-7a was not depleted.. Let-7a was depleted from plasma with a target oligo against let-
7a, while miR-16 was not depleted. (D) qRT-PCR analysis of the recovery of plasma miR-16 following incubation with a target mimic fully complementary to
miR-16 or a scrambled target mimic. Materials and Methods and SI Appendix, Fig. S4, describe the protocol for recovering miRNAs from the target mimic
capture beads. “No plasma control” represents incubation of bead-conjugated target mimics in PBS. Relative expression levels shown are normalized to the
spike-in cel-miR-39 and to the scrambled target mimic-incubated plasma supernatant. Error bars represent SE of mean (SEM) derived from three or more
experiments. Statistical significances were determined by Student t tests. (E) Western blot probed with anti-AGO2 antibody to assess the AGO recovered from
the miR-16 and scrambled target mimic-conjugated beads following incubation in plasma. The red arrow shows the AGO2-specific band at ∼97 kDa present in
the sample from the miR-16 target oligo beads and absent from the scrambled oligo beads.










































detected in addition to let-7a. In this respect, we note that, in our
small RNA sequencing data, the cumulative average depletion of
let-7 family members (let-7a, let-7b, let-7c, let-d, let-7e, let-7f,
let-7g, and let-7i) was ∼34% (SI Appendix, Fig. S7F).
These results using affinity matrix-linked target mimics against
miR-16 and let-7a show that circulating miR-16 and let-7 retain
the capacity to engage in sequence-specific target binding in a
manner consistent with their association with active miRISC.
Stoichiometry of miRNA and Argonaute in Circulating miRISC/AGO2
Complexes. We quantified the amount of AGO2 immunoprecipi-
tated from human plasma by anti-AGO2 antibodies using Western
blotting and a purified human AGO2 protein as a quantification
standard. The results indicate a concentration of antibody-accessible
AGO2 in plasma of ∼35 pM (SI Appendix, Fig. S8). Similarly, we
measured the amount of antibody-accessible AGO2 in CSF to be
∼100-fold less than that in plasma (SI Appendix, Fig. S9 A and B).
This corresponds roughly to the relative levels of certain major
miRNAs in CSF compared with plasma. For example, miR-16 was
estimated to be ∼640 fM in plasma and ∼1.6 fM in CSF (SI Ap-
pendix, Fig. S9 C and D); miR-451 was estimated to be ∼2.6 pM in
plasma and ∼15 fM in CSF (SI Appendix, Fig. S9 E and F).
We then quantified the amount of AGO2 recovered by oligo-
nucleotides complementary to miR-16 or miR-451 (SI Appendix,
Fig. S10). We determined that the amount of AGO2 recovered
from 200 μL of plasma by each miRNA target oligonucleotide was
similar to the amount of the respective miRNA in the same vol-
ume of plasma. miR-16 levels in plasma were determined to be
about 640 fM (SI Appendix, Fig. S9C), which corresponds to ∼0.13
fmoles in 200 μL; the amount of miR-16–bound AGO2 recovered
from 200 μL of plasma was similarly ∼0.1 fmoles (SI Appendix, Fig.
S10 A and B). Likewise, miR-451 levels in plasma were deter-
mined to be an average of ∼2.6 pM (SI Appendix, Fig. S9E), which
corresponds to ∼0.5 fmoles per 200 μL; the amount of miR-
451–bound AGO2 recovered from 200 μL of plasma was deter-
mined to be ∼0.56 fmoles (SI Appendix, Fig. S10 C and D). The
essentially 1:1 ratio between the respective circulating miRNA and
the AGO2 recovered by miRNA-specific target mimic supports
the conclusion that circulating miR-16 and miR-451 are associated
with bona fide miRISC.
Stability of Circulating miRISC Complexes against Sample Freeze/
Thaw Cycles and during Incubations for Immunoprecipitation and
Target Oligo Capture. Generally, our fresh plasma and CSF sam-
ples were aliquoted and frozen at −80 °C and thawed at the time
Fig. 6. Target mimic oligonucleotides specifically deplete their complementary miRNAs. (A and B) Small-RNA sequencing of plasma supernatant following
incubation with scrambled oligonucleotide (x-axis) or miR-16 (n = 3; A) or let-7a (n = 2; B) target mimic (y-axis). (C and D) Deseq2 statistical analysis conducted
with FDR threshold at 5% (adjusted P value ≤ 0.05) and fold change set to >2 shows the miRNAs that are depleted in a statistically significant manner by miR-
16 target mimic (C) or let-7a target mimic (D). The UMI counts are normalized to the spike-in cel-miR-39.


























































of the experiments. Therefore, it was a formal possibility that
some of the properties of circulating miRISC that we observed,
such as their accessibility to immunoprecipitation by anti-AGO2
antibodies and base-pairing with target oligonucleotides, could
be a consequence of their release from the protection of hypo-
thetical higher-order complexes by a single cycle of freezing
and thawing.
Accordingly, fresh (never frozen) plasma samples were col-
lected from volunteers, split into aliquots, and, for each sample,
one never-frozen aliquot was kept in ice (4 °C) for (immediate)
further analysis while another aliquot was subjected to one cycle
of freezing (−80 °C). Both the freeze-thawed aliquots and the
fresh (never-frozen) aliquots were processed in parallel for
AGO2 immunoprecipitation or target mimic oligo pull-down and
subsequent small RNA extraction.
We observed very similar patterns of miRNA depletion by
AGO2 immunoprecipitation from frozen vs. fresh aliquots of
plasma, where essentially none of the miRNAs showed statistical
significance (Deseq2) in depletion between fresh vs. frozen
samples (SI Appendix, Fig. S11)
Likewise, we used a 2′-O-methyl oligonucleotide target mimic
to pull down miR-16 from frozen and fresh aliquots of otherwise
identical plasma samples and observed that the miR-16 family
and the miR-107/103 family miRNAs were depleted (Deseq2)
similarly from plasma for both the fresh and the frozen samples
(SI Appendix, Fig. S12).
To evaluate whether the stability of circulating miRNAs
detectable in plasma can be appreciably affected by freeze-
thawing or by the incubation conditions associated with our
immunoprecipitation and target mimic pull-down experiments,
we compared the abundance of miRNAs via small RNA se-
quencing between otherwise identical aliquots of fresh plasma
samples (never frozen; maintained on ice) that were either
processed immediately for RNA extraction (“Fresh” in SI
Appendix, Fig. S13) and frozen (−80 °C) and thawed (SI Ap-
pendix, Fig. S13 A and B) or never-frozen plasma samples left
at room temperature (∼22 °C) for 30 min (which corresponds
to the target mimic pull-down conditions; SI Appendix, Fig.
S13 C and D) or never-frozen plasma samples left overnight at
4 °C (which corresponds to the immunoprecipitation condi-
tions; SI Appendix, Fig. S13 E and F). In none of these com-
parisons did we detect appreciable changes (Deseq2 analysis)
in miRNA profiles; the only noted exception was that miR-145-
3p levels were decreased during the 30-min room temperature
incubation.
These findings indicate that abundances of miRNAs in our
plasma samples, and the accessibility of miRNA::carrier com-
plexes to immunoprecipitation by anti-AGO2 or target mimic
pull-down, is not an artifact of using frozen samples, nor are
there appreciable changes in miRNA abundance over the course
of our experimental incubations (SI Appendix, Figs. S11–S13).
miRNA Depletion by AGO2 Immunoprecipitation of CSF from Normal
Controls Compared to Patients with CNS Pathologies. We conduced
AGO2 immunoprecipitation using CSF samples from amyo-
trophic lateral sclerosis (ALS) patients and observed a pattern
of miRNA depletion that differed from that observed in
healthy CSF samples. Fewer miRNAs were efficiently de-
pleted from ALS CSF compared with CSF from healthy in-
dividuals (Fig. 4 A–D). Overall, most miRNAs detected in
normal CSF were depleted to varying levels by AGO2 immu-
noprecipitation (average depletion of ∼62%; n = 3), while
certain miRNAs in ALS CSF appear to be resistant to de-
pletion by AGO2 immunoprecipitation (average depletion of
∼45%; n = 3). For example, miR-203b-5p, miR-150-5p, and
miR-676 were ∼54% (P = 0.02), ∼64% (P = 0.01), and ∼59%
(P = 0.0003) depleted, respectively, in healthy control CSF by
AGO2 immunoprecipitation, while miR-203b-5p was not
depleted at all (0%; P = 5.0E-324) and miR-150-5p and miR-
676 were only ∼31% (P = 0.03) and ∼36% (P = 0.003) de-
pleted, respectively, in ALS CSF samples. Similarly, miR-3168
and miR-625-3p were 69% (P = 0.1) and 61% (P = 0.01) de-
pleted, respectively, following AGO2 immunoprecipitation in
healthy control CSF samples, but appear to be refractory to
depletion (P = 0.058) in ALS CSF (Fig. 4B and Datasets S4
and S5). These observations suggest that certain miRNAs may
be associated with either of the two broad classes of immu-
nologically distinguishable complexes in CSF, depending on
the pathophysiological conditions. Under normal physiologi-
cal conditions, CSF miRNAs appear to be primarily associated
with miRISC/AGO2 complexes that are accessible by anti-
AGO2 antibodies, while, under certain pathological condi-
tions, CSF miRNA may be associated with complexes that are
unable to interact with AGO2 antibodies.
We also conducted AGO2 immunoprecipitation in 400 μL of
CSF from patients with elevated intracranial pressure (ICP).
AGO2 immunoprecipitation from ICP CSF (Fig. 4C) resulted
in a pattern of miRNA depletion that was different from
normal CSF. Similar to what was observed in ALS CSF, certain
miRNAs were resistant to AGO2 immunoprecipitation (aver-
age depletion of ∼48%; Fig. 4F). For example, miR-203b-5p,
miR-203a-3p, miR-152-5p, miR-1911-5p, and miR-138-2-3p
were each more than 50% depleted (P ≤ 0.05) in healthy
control CSF, while they were completely refractory to deple-
tion (P ≤ 0.05) in ICP CSF samples. Similarly, miR-9-5p and
miR-125a-5p were also more than 50% depleted (P ≤ 0.05) by
AGO2 immunoprecipitation in healthy control CSF but were
less than 50% depleted (P ≤ 0.05) in the ICP CSF samples
(Datasets S6 and S7).
Discussion
We observed that almost all of the miRNAs in normal human
plasma could be immunoprecipitated by AGO2 antibodies,
suggesting that the majority of plasma-borne miRNAs are
associated with miRISC/AGO2 complexes that are free to
interact with anti-AGO2 antibodies (Fig. 1). Across 5 inde-
pendent samples of plasma small RNA sequencing, only 11
miRNAs were less than 50% depleted by AGO2 immuno-
precipitation; apparently, a substantial fraction of these 11
miRNAs (miR-155, miR141-3p, miR-375, miR-223-3p, miR-
10b, miR-125a-5p, miR-125b-5p, miR-29b-3p, miR-30e-3p,
miR-30a-5p, and miR-126-3p) are associated with complexes
in which AGO2 is absent or inaccessible to anti-AGO2 anti-
bodies (Fig. 1). It is possible that the antibody-inaccessible
fraction of these 11 miRNAs reflects enclosure within EVs,
as these same miRNAs have been previously reported to be
exosome-associated (15, 35–39). It should be noted that, in
our experiments, some portion of the miRNAs that were not
immunoprecipitated with AGO2 could be associated with
AGO1, AGO3, or AGO4; we did not assess the contribution
of these other Argonautes to circulating miRISC, as our an-
tibody was specific to AGO2.
In support of the conclusion that miRNAs in circulation are
predominantly miRISC-associated, we find that the two miRNAs
that we tested (let-7 and miR-16) can base-pair with a comple-
mentary 2′-O-methyl oligonucleotide target mimic in a sequence-
specific manner. Moreover, the binding of circulating miRNAs to
a target mimic appears to be mediated by seed nucleotide (nu-
cleotides g2 to g8) base pairing. In particular, we observed that
miR-16 family members with identical seed sequences but diver-
gent nonseed (nucleotides g9 to g22) sequences were depleted
from plasma using a target oligo complementary to miR-16.
Further, miR-107/miR-103 family members, which fortuitously
match a portion of the miR-16 target through their seed sequence,
also are efficiently depleted from plasma along with miR-16. The
ability of circulating miRNAs to engage in seed-mediated base










































pairing to a target mimic oligonucleotide is consistent with bona
fide miRISC-mediated target recognition (40–44). Also consistent
with the association of circulating miRNAs with active miRISC,
we find that the amount of AGO2 recovered from plasma by a
target mimic oligo is similar to the amount of the cognate miRNA
in the plasma sample, suggesting a 1:1 ratio between a circulating
miRNA and its AGO2 partner.
In contrast to the miR-16 family members detected, which
were efficiently depleted from plasma by a miR-16 comple-
mentary 2′-O-methyl target mimic oligonucleotide, let-7 family
members were less efficiently depleted by a cognate let-7a target
mimic. One interpretation of this observation is that a portion of
some circulating miRNAs (exemplified by the let-7 family) may
be sequestered within vesicles or in higher-order protein com-
plexes that mask the miRNA in such a way that inhibits the base
pairing with a target mimic. An alternative explanation for in-
efficient depletion of a miRNA from plasma using target mimics
could be the presence of an endogenous cRNA including unre-
leased passenger strand already annealed to the miRNA. How-
ever, we think that this latter explanation is unlikely for two
reasons. First, we did not observe appreciable representation of
passenger strand read counts relative to guide strand reads in our
datasets (SI Appendix, Tables S3–S5). In particular, the let-7
family member with the highest fraction of passenger strand
detected in plasma was let-7d (4.83% of the two strands), while it
was 61% depleted by 2′-OM pull-down (SI Appendix, Table S5).
Second, our RNA sequencing data of plasma supernatant from
control experiments (SI Appendix, Table S6) and of plasma RNA
immunoprecipitated by anti-AGO2 antibody (SI Appendix, Table
S7) did not indicate an appreciable representation of mappable
RNA species other than miRNA.
We observed that the miRNA profile in plasma was not
quantitatively affected by freeze-thawing the sample, nor by the
incubation times and conditions of our immunoprecipitation
and target mimic experimental conditions. Other researchers
have also observed that the levels of miRNAs associated with
exosomes is not affected in frozen plasma compared with fresh
plasma, suggesting that EVs are stable during freeze-thawing
(7). The association of circulating miRNAs with miRISC/
AGO2 complexes could in part account for the remarkable
stability of miRNA in body fluids (5, 6), as miRNA bound to
AGO2 is held in a conformation where the phosphodiester
backbone appears to be protected from nucleases by interac-
tions with AGO2 (45). Moreover, AGO2 loaded with a miRNA
appears to adopt a conformation that is resistant to proteases,
such as thermolysin (46).
Our findings that plasma-borne miRNAs are associated with
miRISC and can sequence-specifically bind to complementary
target oligonucleotides implies that these extracellular miRNAs
could, in principle, contribute to cellular posttranscriptional
gene regulation, provided that they were reinternalized into
cells in sufficient quantities. However, it is important to con-
sider that the intracellular concentrations of a miRNA required
for efficient gene regulation is estimated to be appreciably
greater than ∼20 pM, the Kd for miRISC::target binding (34,
47), and perhaps even in the nanomolar range (4). Our data
confirm previous estimates by others (48–50) that the total
concentration of circulating miRNAs in blood plasma is ap-
proximately ∼5 pM. In our plasma samples, the most abundant
miRNAs, miR-451 and miR-16, are present in concentrations
of ∼2.5 pM and 0.5 pM, respectively, indicating that even these
relatively abundant circulating miRNAs would need to be
concentrated 10 to 1,000 fold upon import into the cytoplasm
of recipient cells in order to be functional. Further in vivo
studies are necessary to determine whether certain circum-
stances could make it possible for cells to import miRNAs at
functional levels from the extracellular milieu.
By analogy with synthetic miRNAs and siRNAs, whose in vivo
delivery to cells are facilitated by the interactions of their ligand
conjugates and the cell surface receptors (51, 52), uptake of
natural extracellular miRISC could be mediated by cell surface
proteins with the capacity to bind AGO2. Neuropilin-1 is one
such cell surface protein suggested to bind AGO2 (53). It is also
likely that the fate of some extracellular miRNAs could be
determined by association (either internally or externally) with
EVs (Fig. 1). Although we observed that the majority of plasma
miRNAs are associated with free miRISC, based on their
ability to readily interact with anti-AGO2 antibody and target
mimics, we did not assess what fraction of circulating miRISC
in our samples could be bound to the exterior surfaces of EVs.
Support for the association of miRISC with EVs comes from
various reports, including the identification of AGO2 and
GW182 in exosomal samples recovered from cell culture me-
dium (25). However, previous studies that have reported EV-
associated miRNAs have generally not included confirmation
of whether the reported miRNAs/miRISC/AGO2 are enclosed
within the EV interior or, alternatively, bound to the exterior
surface of EVs.
Circulating miRNAs have been investigated as potential di-
agnostic markers for numerous diseases, including cancer (11,
12), liver toxicity (14), and neurodegenerative disorders (10, 13).
What has not been explored is the question of possible disease-
related differences in the assortment of circulating miRNAs into
distinct carrier complexes, such as free miRISC/AGO2 and EVs.
It is not yet understood whether the assortment of extracellular
miRNAs into particular complexes may reflect the cell type and/
or pathophysiological status of their cells of origin. Numerous
reports suggest that cells may produce elevated levels of EVs
under pathological conditions, such as in the tumor microenvi-
ronment (54, 55). EV-associated miRNAs have been reported to
be released through a ceramide-dependent secretion pathway
(31), and accumulation of ceramide has been reported in spinal
cords of ALS patients (56) and in brain cortices of Alzheimer’s
disease patients (9).
We observed that extracellular miRNAs in CSF samples
from healthy individuals were predominantly depleted by
AGO2 immunoprecipitation, while CSF from ALS patients
contained a subset of miRNAs that were inefficiently depleted
by AGO2 immunoprecipitation. Similarly, CSF from patients
with elevated intracranial pressure contained a higher portion,
compared to normal CSF, of miRNAs that were not efficiently
depleted by AGO2 immunoprecipitation. These observations
suggest that pathological conditions may alter not only the
overall profile of miRNA levels in CSF (57–59), but also the
profile of miRNA carrier complexes. Further investigations
will be required to characterize the origin and composition of
anti-AGO2–refractory miRNA complexes in CSF and to de-
termine their potential significance as a novel class of diag-
nostic biomarkers in the context of neurological diseases.
More broadly, we suggest that employing methods to resolve
circulating miRNAs profiles into classes of carrier complexes
such as those reported here—free miRISC complexes that are
compliant with AGO2 immunoprecipitation and/or that can
base-pair with a target mimic, and complexes that are refrac-
tory to these biochemical assays—could substantially increase
the specificity of biomarker discovery for diverse pathological
conditions. To this end, it will be important to further char-
acterize in detail the properties and molecular compositions of
extracellular miRNA complexes, both in normal and patho-
logical contexts, and to uncover the cellular processes and
export pathways that produce them.
Materials and Methods
Detailed materials and methods used in all experiments are provided in SI
Appendix, SI Methods. AGO2 immunoprecipitation was conducted according


























































to Arroyo et al. (6), and 2′-O-methyl RNA oligonucleotide target mimic pull-
down assay was conducted according to Jannot et al. (60). Plasma and CSF
RNA was extracted according to Tanriverdi et al. (61), and qRT-PCR was
conducted according to Geekiyanage et al. (9). Small-RNA libraries were
prepared using QIAseq miRNA Library Kit (Qiagen), and RNA sequencing
was conducted using Illumina platforms. Small-RNA sequencing data analysis
was conducted using the Qiagen pipeline, Deseq2 (62), Student t tests, and
debrowser platforms (63).
Human Plasma and CSF Sample Collection. Deidentified human plasma and
CSF samples were collected in accordance with procedures and consent forms
approved by the University of Massachusetts Medical School Institutional Review
Board (IRB 13019_12 and IRB 14047_12). Deidentified healthy control andALS CSF
samples were obtained from the NEALS consortium (https://www.neals.org/).
Data Availability. All study data are included in the article and SI Appendix.
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